Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Barzolvolimab in Prurigo Nodularis
NCT06366750Phase 2Active, not recruiting
- Sponsor
- Celldex Therapeutics
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of barzolvolimab in prurigo nodularis (PN), sponsored by Celldex Therapeutics. Started Apr 2024; status: active, not recruiting.
02
Drugs
barzolvolimab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT06366750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06366750.